Table 2.
Cell Lines | Histological Type | IC50 (95% CI) in µg/mL | ||
---|---|---|---|---|
EO | DOX | 5-FU | ||
Cancer cells | ||||
HepG2 | Human hepatocellular carcinoma | 28.5 (23.8–36.4) |
0.03 (0.01–0.2) |
0.2 (0.1–0.4) |
HCT116 | Human colon carcinoma | >50 | 0.1 (0.1–0.2) |
0.5 (0.3–1.1) |
MCF-7 | Human breast adenocarcinoma | 36.7 (26.7–50.5) |
0.3 (0.2–0.4) |
1.8 (0.7–2.3) |
HL-60 | Human promyelocytic leukemia | 33.51 (27.3–41.2) |
0.04 (0.02–0.08) |
1.6 (1.2–2.2) |
B16-F10 | Mouse melanoma | 39.7 (32.1–49.0) |
0.2 (0.2–0.2) |
0.5 (0.3–0.8) |
Non-cancerous cell | ||||
MRC-5 | Human lung fibroblast | 46.0 (39.6–53.6) |
0.2 (0.1–0.5) |
7.5 (5.2–11.0) |
The data are presented as IC50 values, in μg/mL, with their respective 95% confidence interval (95% CI) obtained by nonlinear regression from three independent experiments carried out in duplicate, as measured by the Alamar blue assay after 72 h of incubation. Doxorubicin (DOX) and 5-fluorouracil (5-FU) were used as positive controls.